Vascular ultrasound contrast agents are gas microbubbles with a diameter less than 10 μm (2 to 5 μm on average for most of the newer agents) to pass through the lung capillaries and enter into the systemic circulation. Air bubbles in that size persist in solution for only a short time; too short for systemic vascular use in medical ultrasound imaging. So the gas bubbles have to be stabilized to persist long enough and survive pressure changes in the heart.
Most vascular contrast media are stabilized against dissolution and coalescence by the presence of additional materials at the gas-liquid interface. In some cases, this material is an elastic solid shell that enhances stability by supporting a strain to counter the effect of surface tension. In other cases, the material is a surfactant, or a combination of two or more surfactants.
Typically the effective duration of vascular enhancement is a few minutes, after which the microbubbles dissipate. This rather short duration of vascular enhancement makes it easy to perform repeated dynamic studies. Intravenous vascular contrast agents will be used in imaging malignant tumors in the liver, kidney, ovary, pancreas, prostate, and breast. Tumor neovascularization can be a marker for angiogenesis, and Doppler signals from small tumor vessels may be detectable after contrast injection. Contrast agents are useful for evaluating vessels in a variety of organs, including those involved in renal, hepatic, and pancreatic transplants. If an area of ischemia or a stenosis is detected after contrast administration, the use of other more expensive imaging modalities, including CT and MRI, can often be avoided.

See also Acoustically Active Lipospheres.

Vector array transducers have phasing applied to linear sequenced arrays to steer pulses in various directions.

Sound waves must have a medium to pass through. The velocity or propagation speed is the speed at which sound waves travel through a particular medium measured in meters per second (m/s) or millimeters per microsecond (mm/μs). Because the velocity of ultrasound waves is constant, the time taken for the wave to return to the probe can be used to determine the depth of the object causing the reflection.
The velocity is equal to the frequency x wavelength.
V = f x l
The velocity of ultrasound will differ with different media. In general, the propagation speed of sound through gases is low, liquids higher and solids highest. The speed of sound depends strongly on temperature as well as the medium through which sound waves are propagating. At 0 °C (32 °F) the speed of sound in air is about 331 m/s (1,086 ft/s; 1,192 km/h; 740 mph; 643 kn), at 20 °C (68 °F) about 343 metres per second (1,125 ft/s; 1,235 km/h; 767 mph; 667 kn)

Velocity (m/s)

Doppler ultrasound visualizes blood flow-velocity information. The peak systolic velocity and the end diastolic velocity are major Doppler parameters, which are determined from the spectrum obtained at the point of maximal vessel narrowing. Peak systolic velocity ratios are calculated by dividing the peak-systolic velocity measured at the site of flow disturbance by that measured proximal of the narrowing (stenosis, graft, etc.).

See Acceleration Index, Acceleration Time, Modal Velocity, Run-time Artifact and Maximum Velocity.

Peripheral veins are easily tested using a 5 to 10 MHz transducer. The venous walls are smooth, thin, and compressible. Venous ultrasound imaging requires the compression of the veins in the transverse view. If compression is performed in the longitudinal view, the vein may roll away from the transducer possibly creating a false-negative examination.
The lumen of the normal vein is echo free. Increasing the gain will display low level echoes representing venous blood moving towards the heart. When performing Doppler spectral analysis or color Doppler the gate should be placed in the center of the vessel. In case of a non-obstructing or recanalized thrombosis, the Doppler gate should be placed within the remaining vessel lumen for flow detection.

See also Maximum Venous Outflow and Zero Offset.

Diagnostic Ultrasound Corporation updated its company name to Verathon Inc. at October 11, 2006.
Verathon Inc. formerly 'Diagnostic Ultrasound' was founded in 1984 by Gerald McMorrow. His vision was to use emerging ultrasound technology to develop noninvasive, easy to use medical devices that would fill unmet needs in health care.
In the beginning, the company was no more than one man working alone in his basement. Today, the company has 150 employees and has sold more than 100 million dollars worth of its products worldwide.

Ultrasound Systems: